Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis

Ann Hepatol. 2020 Sep-Oct;19(5):451-457. doi: 10.1016/j.aohep.2020.04.010. Epub 2020 Jun 6.

Abstract

Infections are a frequent complication and a major cause of death among patients with cirrhosis. The important impact of infections in general and especially spontaneous bacterial peritonitis on the course of disease and prognosis of patients with cirrhosis has been recognized for many years. Nevertheless, such importance has recently increased due to the comprehension of infection as one of the most prominent risk factors for patients to develop acute-on-chronic liver failure. Furthermore, the issue of infections in cirrhosis is a focus of increasing attention because of the spreading of multidrug resistant bacteria, which is an emerging concern among physicians assisting patients with cirrhosis. In the present paper, we will review the current epidemiology of infections in patients with cirrhosis and particularly that of infections caused by resistant bacteria, demonstrating the relevance of the subject. Besides, we will discuss the current recommendations on diagnosis and treatment of different kinds of infections, including spontaneous bacterial peritonitis, and we will highlight the importance of knowing local microbiological profiles and choosing empirical antibiotic therapy wisely. Finally, we will debate the existing evidences regarding the role of volume expansion with albumin in patients with cirrhosis and extraperitoneal infections, and that of antibiotic prophylaxis of spontaneous bacterial peritonitis.

Keywords: Antibiotics; Cirrhosis; Infection; Multidrug-resistant bacteria; Spontaneous bacterial peritonitis.

Publication types

  • Review

MeSH terms

  • Albumins / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / diagnosis
  • Bacterial Infections / drug therapy
  • Bacterial Infections / microbiology*
  • Bacterial Infections / mortality
  • Drug Resistance, Multiple, Bacterial
  • Fluid Therapy
  • Humans
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / mortality
  • Peritonitis / diagnosis
  • Peritonitis / drug therapy
  • Peritonitis / microbiology*
  • Peritonitis / mortality
  • Plasma Substitutes / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Albumins
  • Anti-Bacterial Agents
  • Plasma Substitutes